



## 2nd Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after December 2, 2025

The Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective December 2, 2025 are listed on pages 2-6 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and Community Health Plan of Imperial Valley *Provider Participation Agreement (PPA)*.

The update includes:

- 16 new injectable medications to be added to the DOFR crosswalk
- 40 updates and changes to current injectable medication procedure codes
- 15 new biosimilars and updates to be added to the DOFR Crosswalk
- 3 updates for new generic drugs

#### Additional information

Relevant sections of the Plan's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) > *Provider Library* under Quick Links, or go directly to [providerlibrary.healthnetcalifornia.com](https://providerlibrary.healthnetcalifornia.com).

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141.

#### THIS UPDATE APPLIES TO:

- Participating Physician Groups

#### PROVIDER SERVICES

CHPIV Medi-Cal  
(including ECM and CS providers) –  
833-236-4141

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com)

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0172	Azmiro™	Injection, testosterone cypionate, 1 milligrams (mg)	Therapeutic injection	
J9999	Emrelis™	Telisotuzumab vedotin-tllv for injection, for intravenous (IV) use	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Encelto™	Revakinagene taroretcel-lwey intravitreal implant 200,000 cells	Therapeutic injection	
A9611	Flyrcado™	Flurpiridaz F 18 IV solution 5-55 mCi/ milliliters (ml) (190-2,050 megabecquerels (MBq)/ml)	Diagnostic agent	Not included in DOFR crosswalk
J9999	Grafapex™	Treosulfan for injection for IV use	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Imaavy™	Nipocalimab-Aahu IV solution	Therapeutic injection	
J9249	Ivra™	Melphalan HCl IV solution 90 mg/ml (base equivalent)	Therapeutic injection	Chemotherapy <sup>1</sup>
J0364	Onapgo™	Apomorphine hydrochloride (HCl) solution cartridge	Self-injectable	
J9999	Penpulimab-kcqx	Penpulimab-kcqx injection for IV use	Therapeutic injection	Chemotherapy <sup>1</sup>
J3490	Qfitlia™	Fitusiran injection for subcutaneous use	Therapeutic injection	Blood/blood products for hemophilia
J2547	Rapiblyk™	Landiolol HCl for IV solution 280 mg	Therapeutic injection	
J3590	Ryoncil®	Remestemcel-L-rknd 2 x 3.8 ml suspension for IV infusion kit	Therapeutic injection	
J9342	Tepadina®	Injection, thiotepa, not otherwise specified, 1 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J9341	Tepylute®	Thiotepa for IV solution	Therapeutic injection	Chemotherapy <sup>1</sup>
J9275	Unloxcyt™	Injection, cosibelimab-ipdl, 2 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
90593	Vimkunya™	Chikungunya vaccine recombinant virus-like particle IM suspension pre-filled syringe 40 mcg/0.8ml	Therapeutic injection	Immunization

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

## Updates/changes to injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J3303	Aristospan® intra-articular	Triamcinolone hexacetonl injection	Code deleted
Q2058	Aucatzyl®	Obecabtagene autoleucel suspension for intravenous infusion	Replaces J3590
J3355	Bravelle®	Urofollitropin, 75 international unit (IU)	Discontinued
90684	Capvaxive™	Pneumococcal 21-valent conjugate vaccine injection, for intramuscular use	Replaces J3590
J1020	Depo-medrol® 20	Methylprednisolone 20 mg injection	Code deleted
J1030	Depo-medrol® 40	Methylprednisolone 40 mg injection	Code deleted
J1040	Depo-medrol® 80	Methylprednisolone 80 mg injection	Code deleted
J1010	Depo-medrol®	Injection, methylprednisolone acetate, 1 mg	New code replaces J1020, J1030, J1040
J1100	Dexamethasone sodium phosphate	Dexamethasone sodium phosphate 1 mg	Code deleted
J1180	Dilor	Dyphylline injection	Discontinued
C9304	Hympavzi™	Marstacimab-hncq injection, for subcutaneous use	Replaces J3590
J3391	Lenmeldy™	Atidarsagene autotemcel IV suspension	Replaces J3590
J3490	Luveris®	Lutropin alfa for subcutaneous injection 75 unit	Discontinued
J2919	Solu-medrol®	Methylprednisolone sodium succinate for injection PF 500	Code deleted
J9289	Opdivo qvantig™	Nivolumab and hyaluronidase-nvhy injection, for subcutaneous use	Replaces J9999
J0725	Profasi®	Chorionic gonadotropin/1000 IU	Discontinued
J0725	Profasi HP®	Chorionic gonadotropin/1000 IU	Discontinued
J3590	Repronex®	Menotropins 75 IU	Discontinued

**Updates/changes to injectable medication procedure codes or HCPCS codes, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>Q9998</b>	Selarsdi™	ustekinumab-aekn is biosimilar* to Stelara®	Replace J3590
<b>J1720</b>	Solu-cortef®	Hydrocortisone sodium succinate	Code deleted
<b>Q5099</b>	Steqeyma®	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	Replaces J3590
<b>J1590</b>	Tequin®	Gatifloxacin injection	Discontinued
<b>J2725</b>	Thyrel® TRH	Protirelin per 250 mcg	Discontinued
<b>S0040</b>	Ticarcillin	Ticarcillin disodium	Discontinued
<b>J0365</b>	Trasyol®	Aprotonin, 10,000 Kallikrein Inactivator Units (KIU)	Discontinued
<b>J3301</b>	Triamcinolone acetonide USP	Triamcinolone acetonide injection	Code deleted
<b>J1642</b>	Vasceze™	Heparin sodium injection per 10 USP	Discontinued
<b>90393</b>	Vaccinia	Vaccinia immune globulin (VIG), human, intramuscular (IM)	Discontinued
<b>J0900</b>	Valertest #1	Testosterone enanthate and estradiol valerate	Discontinued
<b>J3372</b>	Vancomycin	Injection, vancomycin hydrochloride	New code
<b>J3400</b>	Vesprin	Triflupromazine hydrochloride (HCl) injection	Discontinued
<b>J9219</b>	Viadur®	Leuprolide acetate implant	Discontinued
<b>J7356</b>	Vyalev™	Foslevodopa-foscarbidopa subcutaneous injection	Replaces J3490
<b>Q5100</b>	Yestintek™	Injection, ustekinumab-kfce (yesintek), biosimilar, 1mg	Replaces J3590
<b>J0691</b>	Xenleta™	Lefamulin injection, for intravenous use	Discontinued
<b>J7513</b>	Zenapax®	Daclizumab 25 mg, parenteral	Discontinued
<b>90736</b>	Zostavax™	Zoster (shingles) vaccine, live, for subcutaneous injection	Discontinued
<b>J9276</b>	Ziihera®	Zanidatamab-hrii injection IV solution	Replaces J9999
<b>J2311</b>	Zimhi™	Injection, naloxone HCl, 1 mg	Replaces J2310
<b>C9303</b>	Vyloy®	Zolbetuximab-clzb	Replaces J9999

## New biosimilars to be added to the DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Bomynta®	Denosumab 120mg/1.7ml, injection, for subcutaneous use (biosimilar to Xgeva®)	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
J3590	Conexence®	Denosumab-bnht injection, for subcutaneous use (biosimilar to Prolia®)	Therapeutic injection	
Q5098	Imuldosa™	Injection, ustekinumab-srlf, (biosimilar for Stelara), 1 mg	Self-injectable	
Q5136	Jubbonti®	Denosumab-bbdz injection solution prefilled syringe (biosimilar to Prolia)	Therapeutic injection	
J3590	Jobevne™	Bevacizumab-nwgd injection, (biosimilar to Avastin®)	Therapeutic injection	
Q5153	Opuviz™	Aflibercept-yszy injection, for intravitreal use (biosimilar to Eylea®)	Therapeutic injection	
Q9999	Otulfi™	Ustekinumab-aaaz solution prefilled syringe 45 mg/0.5ml (biosimilar to Stelara)	Self-injectable	
Q9999	Otulfi™	Ustekinumab-aaaz solution prefilled syringe 90 mg/ml (biosimilar to Stelara)	Self-injectable	
Q9999	Otulfi™	Injection, ustekinumab-aaaz, biosimilar to Stelara, 1 mg, IV	Therapeutic injection	
Q5142	Simlandi®	Adalimumab-ryvk injection (biosimilar to Humira®), 1 mg	Self-injectable	
Q9996	Pyzchiva®	Injection, ustekinumab-ttwe, subcutaneous, 1 mg biosimilar to Stelara	Self-injectable	
Q9997	Pyzchiva®	Injection, ustekinumab-ttwe, IV, 1 mg biosimilar to Stelara	Therapeutic injection	
Q9998	Selarsdi™	Injection, ustekinumab-aekn, 1 mg, biosimilar to Stelara	Self-injectable	

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

**New biosimilars to be added to the DOFR crosswalk, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J3590</b>	Steqeyma®	Injection, ustekinumab-stba, biosimilar to Stelara, 1 mg	Self-injectable	
<b>Q5150</b>	Ahzantive®	Injection, aflibercept-mrbb, biosimilar to Eylea 1 mg	Therapeutic injection	

**New generic injectable medications**

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J0616</b>	Metoprolol	Injection, metoprolol tartrate, 1 mg	Therapeutic injection	
<b>J1954</b>	Leuprolide acetate for depot	Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
<b>J1954</b>	Leuprolide acetate for depot	Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at <http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html>.